CLIF-AKI score predicts KDIGO stage 3 acute kidney injury in intensive care unit patients with acute-on-chronic liver failure

doi:10.3748/wjg.122612

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 48

This Article

(5)

(8)

(0)

(331)

Peer-Review Report of This Article

Supplementary Materials of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Dec 28, 2026; 32(48): 122612
Published online Dec 28, 2026. doi: 10.3748/wjg.122612

Table 1 Baseline characteristics and study outcomes of the derivation and validation cohorts, n (%)/median (interquartile range)

Variable	Derivation cohort, n = 1314	Validation cohort, n = 223	P value
Sex			0.153
Female	526 (40.0)	78 (35.0)
Male	788 (60.0)	145 (65.0)
Age, years	57 (50-65)	56 (49-69)	0.983
BMI, kg/m²	28 (24-33)	23 (21-27)	< 0.001^a
MAP, mmHg	60 (53-67)	87 (80-93)	< 0.001^a
Urine output, mL	1225 (750-1900)	1250 (950-1515)	0.421
Comorbidities
Congestive heart failure	177 (13.5)	11 (4.9)	< 0.001^a
Diabetes	307 (23.4)	34 (15.2)	0.007^a
Hypertension	235 (17.9)	59 (26.5)	0.004^a
Fatty liver disease	89 (6.8)	34 (15.2)	< 0.001^a
Organ support
Mechanical ventilation	351 (26.7)	15 (6.7)	< 0.001^a
Vasopressor use	456 (34.7)	13 (5.8)	< 0.001^a
Medications
Antibiotic	1037 (78.9)	103 (46.2)	< 0.001^a
Furosemide	166 (12.6)	107 (48.0)	< 0.001^a
Spironolactone	122 (9.3)	107 (48.0)	< 0.001^a
Human albumin	309 (23.5)	74 (33.2)	0.003^a
Organ failure
Liver	242 (18.4)	108 (48.4)	< 0.001^a
Kidney	401 (30.5)	24 (10.8)	< 0.001^a
Coagulation	312 (23.7)	53 (23.8)	0.994
Brain	326 (24.8)	39 (17.5)	0.018^a
Circulation	456 (34.7)	13 (5.8)	< 0.001^a
Lung	591 (45.0)	25 (11.2)	< 0.001^a
ACLF grade			< 0.001^a
Grade 1	601 (45.7)	192 (86.1)
Grade 2	425 (32.3)	19 (8.5)
Grade 3	288 (21.9)	12 (5.4)
Outcomes
In-hospital mortality	305 (23.2)	36 (16.1)
KDIGO stage 3 AKI within 14 days	452 (34.4)	68 (30.5)
Laboratory tests
Hemoglobin, g/dL	8.50 (7.20-10.10)	10.70 (8.40-12.80)	< 0.001^a
Platelet, × 10⁹/L	82 (52-133)	71 (50-105)	0.001^a
WBC, × 10⁹/L	12 (8-17)	6 (4-9)	< 0.001^a
Albumin, g/dL	2.80 (2.40-3.20)	2.82 (2.42-3.16)	0.545
Anion gap, mmol/L	16.0 (13.0-19.0)	11.3 (9.6-13.8)	< 0.001^a
BUN, mg/dL	26 (16-39)	15 (10-24)	< 0.001^a
Calcium, mmol/L	1.98 (1.83-2.10)	2.07 (1.96-2.16)	< 0.001^a
Chloride, mmol/L	101 (96-106)	102 (97-105)	0.874
Creatinine, mg/dL	1.10 (0.80-1.70)	0.78 (0.64-1.02)	< 0.001^a
Glucose, mmol/L	8.0 (6.5-10.7)	5.5 (4.8-7.0)	< 0.001^a
Sodium, mmol/L	136 (131-139)	136 (133-139)	0.552
Potassium, mmol/L	4.40 (4.00-4.90)	3.80 (3.38-4.21)	< 0.001^a
INR	1.90 (1.50-2.40)	1.97 (1.61-2.44)	0.014^a
PT, seconds	20 (16-26)	22 (19-26)	< 0.001^a
aPTT, seconds	40 (33-54)	44 (39-52)	< 0.001^a
ALT, U/L	38 (23-71)	63 (29-361)	< 0.001^a
ALP, U/L	112 (76-156)	143 (108-195)	< 0.001^a
AST, U/L	80 (46-165)	108 (57-322)	< 0.001^a
TBil, mg/dL	4 (2-9)	12 (7-20)	< 0.001^a
Lymphocytes, %	8 (5-14)	14 (8-22)	< 0.001^a
Monocytes, %	5.0 (3.1-7.3)	8.3 (6.4-10.1)	< 0.001^a
Neutrophils, %	82 (75-88)	75 (67-83)	< 0.001^a
NLR	4 (3-7)	5 (3-10)	0.016^a
RBC, × 10¹²/L	2.55 (2.08-3.08)	3.15 (2.43-3.88)	< 0.001^a
RDW, %	18.1 (15.9-20.8)	15.8 (14.1-18.9)	< 0.001^a
Severity score
MELD	21 (14-28)	25 (22-32)	< 0.001^a
SOFA	8 (6-11)	6 (5-8)	< 0.001^a
MELD-Na	27 (17-40)	27 (23-33)	0.573

^aP < 0.05.

BMI: Body mass index; MAP: Mean arterial pressure; ACLF: Acute-on-chronic liver failure; AKI: Acute kidney injury; WBC: White blood cell; BUN: Blood urea nitrogen; INR: International normalized ratio; PT: Prothrombin time; aPTT: Activated partial thromboplastin time; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; AST: Aspartate aminotransferase; TBil: Total bilirubin; NLR: Neutrophil-to-lymphocyte ratio; RBC: Red blood cell; MELD: Model for end-stage liver disease; SOFA: Sequential organ failure assessment; MELD-Na: Model for end-stage liver disease-sodium; RDW: Red cell distribution width.

Full Size Table

Citation: Wang N, Tan YW, Zhang PF, Zhou XB, Zhu L. CLIF-AKI score predicts KDIGO stage 3 acute kidney injury in intensive care unit patients with acute-on-chronic liver failure. World J Gastroenterol 2026; 32(48): 122612
URL: https://www.wjgnet.com/1007-9327/full/v32/i48/122612.htm
DOI: https://dx.doi.org/10.3748/wjg.122612

Wang N, Tan YW, Zhang PF, Zhou XB, Zhu L. CLIF-AKI score predicts KDIGO stage 3 acute kidney injury in intensive care unit patients with acute-on-chronic liver failure. World J Gastroenterol 2026; 32(48): 122612 [DOI: 10.3748/wjg.122612]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.